Myelodysplastic syndromes

Common Name(s)

Myelodysplastic syndromes, MYELODYSPLASTIC SYNDROME

Myelodysplastic syndromes (MDS) are a rare group of blood disorders characterized by abnormal development of blood cells within the bone marrow. Individuals with MDS have abnormally low blood cell levels (low blood counts). Signs and symptoms associated with MDS include dizziness, fatigue, weakness, shortness of breath, bruising and bleeding, frequent infections, and headaches. In some cases, MDS may progress to bone marrow failure or an acute leukemia. The exact cause of MDS is unknown. It sometimes runs in families, but no disease-causing gene has been identified. Treatment depends on the affected individual's age, general health, and type of MDS and may include red cell and/or platelet transfusions and antibiotics.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Myelodysplastic syndromes" for support, advocacy or research.

Logo
Aplastic Anemia & MDS International Foundation

The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is the world's leading nonprofit health organization dedicated to supporting patients and families living with aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH), and related bone marrow failure diseases. AA&MDSIF provides answers, support and hope to thousands of patients and their families around the world.

Last Updated: 29 Apr 2014

View Details
National Bone Marrow Transplant Link

The mission of the National Bone Marrow Transplant Link is to help patients, caregivers, and families cope with the social and emotional challenges of bone marrow/stem cell transplant from diagnosis through survivorship by providing vital information and personalized support services.

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Myelodysplastic syndromes" for support, advocacy or research.

Logo
Aplastic Anemia & MDS International Foundation

The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is the world's leading nonprofit health organization dedicated to supporting patients and families living with aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH), and related bone marrow failure diseases. AA&MDSIF provides answers, support and hope to thousands of patients and their families around the world.

http://www.aamds.org/

Last Updated: 29 Apr 2014

View Details
National Bone Marrow Transplant Link

The mission of the National Bone Marrow Transplant Link is to help patients, caregivers, and families cope with the social and emotional challenges of bone marrow/stem cell transplant from diagnosis through survivorship by providing vital information and personalized support services.

http://www.nbmtlink.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Myelodysplastic syndromes" returned 709 free, full-text research articles on human participants. First 3 results:

Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.
 

Author(s): Lisa Pleyer, Sonja Burgstaller, Reinhard Stauder, Michael Girschikofsky, Heinz Sill, Konstantin Schlick, Josef Thaler, Britta Halter, Sigrid Machherndl-Spandl, Armin Zebisch, Angelika Pichler, Michael Pfeilstöcker, Eva-Maria Autzinger, Alois Lang, Klaus Geissler, Daniela Voskova, Dietmar Geissler, Wolfgang R Sperr, Sabine Hojas, Inga M Rogulj, Johannes Andel, Richard Greil

Journal:

 

The MDS-IWG and NCCN currently endorse both FAB and WHO classifications of MDS and AML, thus allowing patients with 20-30 % bone marrow blasts (AML20-30, formerly MDS-RAEB-t) to be categorised and treated as either MDS or AML. In addition, an artificial distinction between AML20-30 ...

Last Updated: 16 Apr 2016

Go To URL
Histiocytoid Sweet Syndrome Is More Frequently Associated With Myelodysplastic Syndromes Than the Classical Neutrophilic Variant: A Comparative Series of 62 Patients.
 

Author(s): Lisa Ghoufi, Nicolas Ortonne, Saskia Ingen-Housz-Oro, Walid Barhoumi, Edouard Begon, Corinne Haioun, Cécile Pautas, Florence Beckerich, Christine Robin, Pierre Wolkenstein, Catherine Cordonnier, Olivier Chosidow, Andréa Toma

Journal: Medicine (Baltimore). 2016 Apr;95(15):e3033.

 

Histiocytoid Sweet syndrome (H-SS) is a histological variant of Sweet syndrome (SS) differing from classical neutrophilic SS (N-SS) by a dermal infiltrate mainly composed of lymphocytes and histiocytoid myeloperoxidase-positive cells. We aimed to report a large series of H-SS and ...

Last Updated: 16 Apr 2016

Go To URL
Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment.
 

Author(s): N Gangat, M M Patnaik, K Begna, A Al-Kali, M R Litzow, R P Ketterling, C A Hanson, A D Pardanani, A Tefferi

Journal:

 

Last Updated: 9 Apr 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Myelodysplastic syndromes" returned 138 free, full-text review articles on human participants. First 3 results:

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes.
 

Author(s): R S Komrokji, A F List

Journal: Ann. Oncol.. 2016 Jan;27(1):62-8.

 

The treatment of patients with myelodysplastic syndromes (MDS) begins with assessment of karyotype and risk. Lenalidomide is approved for the treatment of patients who have transfusion-dependent anemia due to lower-risk MDS with chromosome 5q deletion (del(5q)) with or without additional ...

Last Updated: 19 Dec 2015

Go To URL
Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
 

Author(s): Christopher R Cogle, Bart L Scott, Thomas Boyd, Guillermo Garcia-Manero

Journal: Oncologist. 2015 Dec;20(12):1404-12.

 

The myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal myeloid malignancies characterized by multilineage cytopenias, recurrent cytogenetic abnormalities, and risk of progression to acute myeloid leukemia (AML). AML, which can occur de novo as well as secondary ...

Last Updated: 16 Dec 2015

Go To URL
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
 

Author(s): Guillermo Garcia-Manero

Journal: Am. J. Hematol.. 2015 Sep;90(9):831-41.

 

The myelodysplastic syndromes (MDS) are a very heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). MDS occurs more frequently in older males and in individuals with prior exposure ...

Last Updated: 21 Aug 2015

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Last Updated: 15 Jul 2016

Go to URL
Study of DSP-7888 in Patients With Myelodysplastic Syndrome
 

Status: Recruiting

Condition Summary: Myelodysplastic Syndrome

 

Last Updated: 29 Nov 2016

Go to URL
Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome
 

Status: Recruiting

Condition Summary: Myelodysplastic Syndrome

 

Last Updated: 22 Nov 2016

Go to URL